1 Immunity against PRRS virus

To better understand the development of immunity against PRRS virus, it is first necessary to have an idea of how the immune system works.

From an academic point of view, the immune response is generally divided into innate and adaptive immunity, although it must be considered as a continuous process where close interactions exist.

In short, the key differences between innate and adaptive immunity are in terms of time, specificity and memory.

Innate immunity occurs immediately as a first response to infection. In this phase, cells are activated by conserved molecular patterns associated with pathogens.

Adaptive immunity, characterised by cytokine production, cytotoxic activity and antibody production, occurs later.

In this stage, cells are able to respond to specific antigens; to this end, the processing and presentation of the antigens are essential.

In adaptive immunity, subpopulations of B and T cells can survive as memory cells.

After re-exposure to the same antigen, these specific-antigen memory cells can rapidly mobilise. As a result, the adaptive immunity will respond rapidly and effectively to pathogens that have been encountered previously.

The following figure summarises the actors and components that participate in innate and adaptive immunity. Innate immunity includes important processes such as inflammation and antigen presentation.

As can be observed, antigen processing and presentation is essential to correct development of adaptive immunity:

Innate Immunity:

As we have seen, innate immunity recognises and responds to pathogens in a generic way and it does not confer long-lasting immunity. Thus, its main feature is the ability to respond quickly and broadly against infections and other problems/alterations.

Apart from natural barriers, innate immunity includes both humoral (complement system, cytokines, etc.) and cell-mediated immunity components.

The components of cell-mediated immunity include: granulocytes (basophils, eosinophils and neutrophils), macrophages, mast cells, dendritic cells and natural killers.

Although it might seem that innate immunity is just a coarse first line of defense against infections, it is essential for the development of adaptive immunity.

In fact, innate signals drive the activation and polarisation of the four major T helper (Th) subtypes, which are key elements in adaptive immune responses. As Ths are unable to recognise antigens by themselves, antigen processing and presentation by antigen-presenting cells (APCs) is required. APCs include dendritic cells (DCs), macrophages and B cells; however, DCs are considered the professional APC for the priming of naïve T cells.

Thus, it can be said say that DCs are a bridge that connects innate and adaptive immunity.

The differentiation and polarisation of T helpers is driven by APCs. The co-stimulatory molecules present in the surface of APCs and the released cytokines that are present in the immediate cell milieu act as the signals that drive the activation and polarisation of the four major T helper (Th) subtypes.

Adaptive Immunity:

As we have seen, APCs interact with Th and induce their polarisation to the four major T helper (Th) subtypes: Th1, Th2, Th17 and Treg cells.

  • Th1 cells. The main cytokine released by Th1 cells is IFN-γ. Th1 participate mainly in protection against viral infection though IFN-γ and the activation of cytotoxic lymphocytes, which kill virus-infected cells. IFN-γ can also activate macrophages. Th1 cells also help B cells for antibody production.
  • Th2 cells. This Th subtype plays a central role in antibody production, secreting cytokines that participate in the activation and differentiation of B cells into B plasma cells, also known as antibody factories.
  • Th17 cells. These cells play a crucial role in extracellular pathogens (bacteria and fungi), recruiting and activating neutrophils and macrophages. It seems that Th17 are also induced during viral infection, but their role in the protection against viruses is still unclear.
  • Treg. As implied by their name, the major function of Treg cells is to regulate immune responses. They are very useful for preventing the development of responses against self-antigens (autoimmunity) and limiting an excessive immune response against a pathogen (infection-induced immunopathology).

The image below shows an overview of the adaptive immune response (Th polarisation towards Th1 or Th2) after virus recognition by APCs.

Antigen-presenting cells (APCs) process and present the antigen to the T cell Th0. Signals from the APCs before and during the antigen presentation drive differentiation and expansion of Th cell subtypes.

Th1 polarisation produces IL-2, IFN-γ and TNF-α. This results in activation and differentiation of the cytotoxic lymphocytes, which directly kill virus-infected cells.

Activated Th2 cells produce B cell-stimulating cytokines that promote B cell differentiation into B plasma cells, which produce large amounts of antibodies.

Th1-Th2 polarisation

© Laboratorios Hipra, S.A. 2023. All Rights Reserved.
No part of this website or any of its contents may be reproduced, copied, modified or adapted, without the prior written consent of HIPRA.

References

  • Albina E, Carrat C, Charley B. Interferon-alpha response to swine arterivirus (PoAV), the porcine reproductive and respiratory syndrome virus. J Interferon Cytokine Res. 1998, 18:485-90.
  • Ansari IH, Kwon B, Osorio FA, Pattnaik AK. Influence of N-linked glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, antigenicity, and ability to induce neutralizing antibodies. J Virol. 2006, 80:3994–4004.
  • Badaoui B, Rutigliano T, Anselmo A, Vanhee M, Nauwynck H, Giuffra E, Botti S. RNA-sequence analysis of primary alveolar macrophages after in vitro infection with porcine reproductive and respiratory syndrome virus strains of differing virulence. PLoS One. 2014, 9:e91918.
  • Balasuriya UB, MacLachlan NJ. The immune response to equine arteritis virus: potential lessons for other arteriviruses. Vet Immunol Immunopathol. 2004, 102:107-29.
  • Baumann A, Mateu E, Murtaugh MP, Summerfield A. Impact of genotype 1 and 2 of porcine reproductive and respiratory syndrome viruses on interferon-α responses by plasmacytoid dendritic cells. Vet Res. 2013, 44:33.
  • Bautista EM, Molitor TW. Cell-mediated immunity to porcine reproductive and respiratory syndrome virus in swine. Viral Immunol. 1997, 10: 83-94.
  • Bautista EM, Molitor TW. IFN gamma inhibits porcine reproductive and respiratory syndrome virus replication in macrophages. Arch Virol. 1999, 144:1191-200.
  • Buddaert W, Van Reeth K, Pensaert M. In vivo and in vitro interferon (IFN) studies with the porcine reproductive and respiratory syndrome virus (PRRSV). Adv Exp Med Biol. 1998, 440:461-7.
  • Burgara-Estrella A, Díaz I, Rodríguez-Gómez IM, Essler SE, Hernández J, Mateu E. Predicted peptides from non-structural proteins of porcine reproductive and respiratory syndrome virus are able to induce IFN-γ and IL-10. Viruses. 2013, 5:663-77.
  • Butler JE, Lager KM, Golde W, Faaberg KS, Sinkora M, Loving C, Zhang YI. Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic. Immunol Res. 2014, 59:81-108.
  • Calzada-Nova G, Schnitzlein WM, Husmann RJ, Zuckermann FA. North American porcine reproductive and respiratory syndrome viruses inhibit type I interferon production by plasmacytoid dendritic cells. J Virol. 2011, 85:2703-13.
  • Calzada-Nova G, Schnitzlein W, Husmann R, Zuckermann FA. Characterization of the cytokine and maturation responses of pure populations of porcine plasmacytoid dendritic cells to porcine viruses and toll-like receptor agonists. Vet Immunol Immunopathol. 2010, 135:20-33.
  • Cancel-Tirado SM, Evans RB, Yoon KJ. Monoclonal antibody analysis of porcine reproductive and respiratory syndrome virus epitopes associated with antibody-dependent enhancement and neutralization of virus infection. Vet Immunol Immunopathol. 2004, 102:249-62.
  • Cao J, Grauwet K, Vermeulen B, Devriendt B, Jiang P, Favoreel H, Nauwynck H. Suppression of NK cell-mediated cytotoxicity against PRRSV-infected porcine alveolar macrophages in vitro. Vet Microbiol. 2013, 164:261-9.
  • Chen Z, Zhou X, Lunney JK, Lawson S, Sun Z, Brown E, Christopher-Hennings J, Knudsen D, Nelson E, Fang Y. Immunodominant epitopes in nsp2 of porcine reproductive and respiratory syndrome virus are dispensable for replication, but play an important role in modulation of the host immune response. J Gen Virol. 2010, 91:1047-57.
  • Choi CS, Christianson WT, Collins JE, Joo HS, Molitor T. Antibody dependent enhancement of SIRS virus replication. Am Assoc Swine Pract Newsl. 1992, 4:30.
  • Chung HK, Chae C. Expression of interleukin-10 and interleukin-12 in piglets experimentally infected with porcine reproductive and respiratory syndrome virus (PRRSV). J Comp Pathol. 2003, 129:205-12.
  • Costers S, Vanhee M, Van Breedam W, Van Doorsselaere J, Geldhof M, Nauwynck HJ. GP4-specific neutralizing antibodies might be a driving force in PRRSV evolution. Virus Res. 2010, 154:104-13.
  • Costers S, Lefebvre DJ, Goddeeris B, Delputte PL, Nauwynck HJ. Functional impairment of PRRSV-specific peripheral CD3+CD8high cells. Vet Res. 2009, 40:46.
  • Darwich L, Díaz I, Mateu E. Certainties, doubts and hypotheses in porcine reproductive and respiratory syndrome virus immunobiology. Virus Res. 2010, 154:123-32.
  • Darwich L, Gimeno M, Sibila M, Diaz I, de la Torre E, Dotti S, Kuzemtseva L, Martin M, Pujols J, Mateu E. Genetic and immunobiological diversities of porcine reproductive and respiratory syndrome genotype I strains. Vet Microbiol. 2011, 150:49-62.
  • de Lima M, Pattnaik AK, Flores EF, Osorio FA. Serologic marker candidates identified among B-cell linear epitopes of Nsp2 and structural proteins of a North American strain of porcine reproductive and respiratory syndrome virus. Virology. 2006, 30:410–421.
  • Díaz I, Darwich L, Pappaterra G, Pujols J, Mateu E. Immune responses of pigs after experimental infection with a European strain of Porcine reproductive and respiratory syndrome virus. J Gen Virol. 2005, 86:1943-51.
  • Díaz I, Darwich L, Pappaterra G, Pujols J, Mateu E. Different European-type vaccines against porcine reproductive and respiratory syndrome virus have different immunological properties and confer different protection to pigs. Virology. 2006, 351:249-59.
  • Díaz I, Pujols J, Ganges L, Gimeno M, Darwich L, Domingo M, Mateu E. In silico prediction and ex vivo evaluation of potential T-cell epitopes in glycoproteins 4 and 5 and nucleocapsid protein of genotype-I (European) of porcine reproductive and respiratory syndrome virus. Vaccine. 2009, 27:5603-11.
  • Díaz I, Gimeno M, Darwich L, Navarro N, Kuzemtseva L, López S, Galindo I, Segalés J, Martín M, Pujols J, Mateu E. Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection. Vet Res. 2012, 19:43:30.
  • Dokland T. The structural biology of PRRSV. Virus Res. 2010, 154:86-97.
  • Dwivedi V, Manickam C, Binjawadagi B, Linhares D, Murtaugh MP, Renukaradhya GJ. Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. Virol J. 2012, 9:45.
  • EvansAB, Loyd H, Dunkelberger JR, van Tol S, Bolton MJ, Dorman KS, Dekkers JCM, Carpenter S. Antigenic and Biological Characterization of ORF2-6 Variants at Early Times Following PRRSV Infection. 2017, 16;9(5). pii: E113. doi: 10.3390/v9050113.
  • Faaberg KS, Hocker JD, Erdman MM, Harris DL, Nelson EA, Torremorell M, Plagemann PG. Neutralizing antibody responses of pigs infected with natural GP5 N-glycan mutants of porcine reproductive and respiratory syndrome virus. Viral Immunol. 2006, 19:294-304.
  • Fan B, Liu X, Bai J, Zhang T, Zhang Q, Jiang P. Influence of the amino acid residues at 70 in M protein of porcine reproductive and respiratory syndrome virus on viral neutralization susceptibility to the serum antibody. Virol J. 2016, 22:51. doi: 10.1186/s12985-016-0505-7.
  • Fang L, Jiang Y, Xiao S, Niu C, Zhang H, Chen H. Enhanced immunogenicity of the modified GP5 of porcine reproductive and respiratory syndrome virus. Virus Genes. 2006, 32:5–11.
  • Gimeno M, Darwich L, Diaz I, de la Torre E, Pujols J, Martín M, Inumaru S, Cano E, Domingo M, Montoya M, Mateu E. Cytokine profiles and phenotype regulation of antigen presenting cells by genotype-I porcine reproductive and respiratory syndrome virus isolates. Vet Res. 2011, 18:42:9.
  • Gómez-Laguna J, Salguero FJ, Pallarés FJ, Carrasco L. Immunopathogenesis of porcine reproductive and respiratory syndrome in the respiratory tract of pigs. Vet J. 2013, 195:148-55.
  • Gómez-Laguna J, Salguero FJ, Barranco I, Pallarés FJ, Rodríguez-Gómez IM, Bernabé A, Carrasco L. Cytokine expression by macrophages in the lung of pigs infected with the porcine reproductive and respiratory syndrome virus. J Comp Pathol. 2010, 142:51-60.
  • GuW, Guo L, Yu H, Niu J, Huang M, Luo X, Li R, Tian Z, Feng L, Wang Y. Involvement of CD16 in antibody-dependent enhancement of porcine reproductive and respiratory syndrome virus infection. J Gen Virol. 2015,  96:1712-22.
  • Han M, Kim CY, Rowland RR, Fang Y, Kim D, Yoo D. Biogenesis of non-structural protein 1 (nsp1) and nsp1-mediated type I interferon modulation in arteriviruses. Virology. 2014, 458-459:136-50.
  • He Q, Li Y, Zhou L, Ge X, Guo X, Yang H. Both Nsp1β and Nsp11 are responsible for differential TNF-α production induced by porcine reproductive and respiratory syndrome virus strains with different pathogenicity in vitro. Virus Res. 2015, 201:32-40.
  • Huang C, Zhang Q, Guo XK, Yu ZB, Xu AT, Tang J, Feng WH. Porcine reproductive and respiratory syndrome virus nonstructural protein 4 antagonizes beta interferon expression by targeting the NF-κB essential modulator. J Virol. 2014, 88:10934-45.
  • Ke H, Yoo D. The viral innate immune antagonism and an alternative vaccine design for PRRS virus. Vet Microbiol. 2017, 209:75-89.
  • Kim WI, Lee DS, Johnson W, Roof M, Cha SH, Yoon KJ. Effect of genotypic and biotypic differences among PRRS viruses on the serologic assessment of pigs for virus infection. Vet Microbiol. 2007, 123:1-14.
  • Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, Stockhofe-Zurwieden N. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine. 2009, 27:3704-18.
  • Kuzemtseva L, de la Torre E, Martín G, Soldevila F, Ait-Ali T, Mateu E, Darwich L. Regulation of toll-like receptors 3, 7 and 9 in porcine alveolar macrophages by different genotype 1 strains of porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol. 2014, 158:189-98.
  • Lager KM, Mengeling WL, Brockmeier SL. Homologous challenge of porcine reproductive and respiratory syndrome virus immunity in pregnant swine. Vet Microbiol. 1997, 58:113-25.
  • Lamontagne L, Page C, Larochelle R, Longtin D, Magar R. Polyclonal activation of B cells occurs in lymphoid organs from porcine reproductive and respiratory syndrome virus (PRRSV)-infected pigs. Vet Immunol Immunopathol. 2001, 82:165-82.
  • Lamontagne L, Page C, Larochelle R, Magar R. Porcine reproductive and respiratory syndrome virus persistence in blood, spleen, lymph nodes, and tonsils of experimentally infected pigs depends on the level of CD8high T cells. Viral Immunol. 2003, 16:395-406.
  • Lee SM, Schommer SK, Kleiboeker SB. Porcine reproductive and respiratory syndrome virus field isolates differ in in vitro interferon phenotypes. Vet Immunol Immunopathol. 2004, 102:217-31.
  • Li Y, Zhu L, Lawson SR, Fang Y. Targeted mutations in a highly conserved motif of the nsp1β protein impair the interferon antagonizing activity of porcine reproductive and respiratory syndrome virus. J Gen Virol. 2013, 94:1972-83.
  • Loemba HD1, Mounir S, Mardassi H, Archambault D, Dea S. Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus. Arch Virol. 1996, 141:751-61.
  • Lohse L, Nielsen J, Eriksen L. Temporary CD8+ T-cell depletion in pigs does not exacerbate infection with porcine reproductive and respiratory syndrome virus (PRRSV). Viral Immunol. 2004, 17:594-603.
  • Lopez OJ, Osorio FA. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol. 2004, 102:155-63.
  • Loving CL, Brockmeier SL, Sacco RE. Differential type I interferon activation and susceptibility of dendritic cell populations to porcine arterivirus. Immunology. 2007, 120:217-29.
  • Lowe JE, Husmann R, Firkins LD, Zuckermann FA, Goldberg TL. Correlation of cell-mediated immunity against porcine reproductive and respiratory syndrome virus with protection against reproductive failure in sows during outbreaks of porcine reproductive and respiratory syndrome in commercial herds. J Am Vet Med Assoc. 2005, 226:1707-11.
  • Lunney JK, Benfield DA, Rowland RR. Porcine reproductive and respiratory syndrome virus: an update on an emerging and re-emerging viral disease of swine. Virus Res. 2010, 154:1-6.
  • Lunney JK, Fang Y, Ladinig A, Chen N, Li Y, Rowland B, Renukaradhya GJ. Porcine reproductive and respiratory syndrome virus (PRRSV): Pathogenesis and Interaction with the Immune System. Annu Rev Anim Biosci. 2016, 4:129-54
  • Magar R, Larochelle R, Nelson EA, Charreyre C. Differential reactivity of a monoclonal antibody directed to the membrane protein of porcine reproductive and respiratory syndrome virus. Can J Vet Res. 1997, 61:69-71.
  • Martelli P, Gozio S, Ferrari L, Rosina S, De Angelis E, Quintavalla C, Bottarelli E, Borghetti P. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity. Vaccine. 2009, 27:3788-99.
  • Martínez-Lobo FJ, Díez-Fuertes F, Simarro I, Castro JM, Prieto C. Porcine Reproductive and Respiratory Syndrome Virus isolates differ in their susceptibility to neutralization. Vaccine. 2011, 29:6928-40.
  • Mateu E, Diaz I. The challenge of PRRS immunology. Vet J. 2008, 177:345-51.
  • Meier WA, Galeota J, Osorio FA, Husmann RJ, Schnitzlein WM, Zuckermann FA. Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination. Virology. 2003, 309:18-31.
  • Mengeling WL, Lager KM, Vorwald AC, Koehler KJ. Strain specificity of the immune response of pigs following vaccination with various strains of porcine reproductive and respiratory syndrome virus. Vet Microbiol. 2003, 93:13-24.
  • Meulenberg JJ, van Nieuwstadt AP, van Essen-Zandbergen A, Bos-de Ruijter JN, Langeveld JP, Meloen RH. Localization and fine mapping of antigenic sites on the nucleocapsid protein N of porcine reproductive and respiratory syndrome virus with monoclonal antibodies. Virology. 1998, 252:106-14.
  • Murtaugh MP, Xiao Z, Zuckermann F. Immunological responses of swine to porcine reproductive and respiratory syndrome virus infection. Viral Immunol. 2002, 15:533-47.
  • Murtaugh MP, Genzow M. Immunological solutions for treatment and prevention of porcine reproductive and respiratory syndrome (PRRS). Vaccine. 2011, 29:8192-204.
  • Murtaugh MP, Stadejek T, Abrahante JE, Lam TT, Leung FC. The ever-expanding diversity of porcine reproductive and respiratory syndrome virus. Virus Res. 2010, 154:18-30.
  • Nauwynck HJ, Van Gorp H, Vanhee M, Karniychuk U, Geldhof M, Cao A, Verbeeck M, Van Breedam W. Micro-dissecting the pathogenesis and immune response of PRRSV infection paves the way for more efficient PRRSV vaccines. Transbound Emerg Dis. 2012, 1:50-4.
  • Nelson EA, Christopher-Hennings J, Benfield DA. Serum immune responses to the proteins of porcine reproductive and respiratory syndrome (PRRS) virus. J Vet Diagn Invest. 1994, 6:410-5.
  • Oleksiewicz MB, Bøtner A, Toft P, Normann P, Storgaard T. Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes. J Virol. 2001, 75:3277-90.
  • Ostrowski M, Galeota JA, Jar AM, Platt KB, Osorio FA, Lopez OJ. Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J Virol. 2002, 76:4241-50.
  • Rose N, Renson P, Andraud M, Paboeuf F, Le Potier MF, Bourry O. Porcine reproductive and respiratory syndrome virus (PRRSv) modified-live vaccine reduces virus transmission in experimental conditions. Vaccine. 2015, 33:2493-9.
  • Pileri E, Gibert E, Soldevila F, García-Saenz A, Pujols J, Diaz I, Darwich L, Casal J, Martín M, Mateu E. Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model. Vet Microbiol. 2015, 175:7-16.
  • Pirzadeh B, Dea S. Monoclonal antibodies to the ORF5 product of porcine reproductive and respiratory syndrome virus define linear neutralizing determinants. J Gen Virol. 1997, 78: 1867–73.
  • Prieto C, Alvarez E, Martínez-Lobo FJ, Simarro I, Castro JM. Similarity of European porcine reproductive and respiratory syndrome virus strains to vaccine strain is not necessarily predictive of the degree of protective immunity conferred. Vet J. 2008, 175:356-63.
  • Rascón-Castelo E, Burgara-Estrella A, Mateu E, Hernández J. Immunological features of the non-structural proteins of porcine reproductive and respiratory syndrome virus. Viruses. 2015, 7:873-86.
  • Reiner G. Genetic resistance – an alternative for controlling PRRS? Porcine Health Manag. 2016, 2:27.
  • Ren JQ, Sun WC, Lu HJ1, Wen SB, Jing J, Yan FL, Liu H, Liu CX, Xiao PP, Chen X, Du SW, Du R, Jin NY. Construction and immunogenicity of a DNA vaccine coexpressing GP3 and GP5 of genotype-I porcine reproductive and respiratory syndrome virus. BMC Vet Res. 2014, 10:128.
  • Ren J, Lu H, Wen S, Sun W, Yan F, Chen X, Jing J, Liu H, Liu C, Xue F, Xiao P, Xin S, Jin N. Enhanced immune responses in pigs by DNA vaccine coexpressing GP3 and GP5 of European type porcine reproductive and respiratory syndrome virus. J Virol Methods. 2014, 206:27-37.
  • Roca M, Gimeno M, Bruguera S, Segalés J, Díaz I, Galindo-Cardiel IJ, Martínez E, Darwich L, Fang Y, Maldonado J, March R, Mateu E. Effects of challenge with a virulent genotype II strain of porcine reproductive and respiratory syndrome virus on piglets vaccinated with an attenuated genotype I strain vaccine. Vet J. 2012, 193:92-6.
  • Rodríguez-Gómez IM, Gómez-Laguna J, Carrasco L. Impact of PRRSV on activation and viability of antigen presenting cells. World J Virol. 201, 2:146-51.
  • Royaee AR, Husmann RJ, Dawson HD, Calzada-Nova G, Schnitzlein WM, Zuckermann FA, Lunney JK. Deciphering the involvement of innate immune factors in the development of the host response to PRRSV vaccination. Vet Immunol Immunopathol. 2004, 102:199-216.
  • Samsom JN, de Bruin TG, Voermans JJ, Meulenberg JJ, Pol JM, Bianchi AT. Changes of leukocyte phenotype and function in the broncho-alveolar lavage fluid of pigs infected with porcine reproductive and respiratory syndrome virus: a role for CD8(+) cells. J Gen Virol. 2000, 81:497-505.
  • Scortti M, Prieto C, Martínez-Lobo FJ, Simarro I, Castro JM. Effects of two commercial European modified-live vaccines against porcine reproductive and respiratory syndrome viruses in pregnant gilts. Vet J. 2006, 172:506-14.
  • Shimizu M, Yamada S, Kawashima K, Ohashi S, Shimizu S, Ogawa T. Changes of lymphocyte subpopulations in pigs infected with porcine reproductive and respiratory syndrome (PRRS) virus. Vet Immunol Immunopathol. 1996, 50:19-27.
  • Silva-Campa E, Mata-Haro V, Mateu E, Hernández J. Porcine reproductive and respiratory syndrome virus induces CD4+CD8+CD25+Foxp3+ regulatory T cells (Tregs). Virology. 2012, 430:73-80.
  • Sun Y, Han M, Kim C, Calvert JG, Yoo D. Interplay between interferon-mediated innate immunity and porcine reproductive and respiratory syndrome virus. Viruses. 2012, 4:424-46.
  • Takikawa N, Kobayashi S, Ide S, Yamane Y, Tanaka Y, Yamagishi H. Detection of antibodies against porcine reproductive and respiratory syndrome (PRRS) virus in swine sera by enzyme-linked immunosorbent assay. J Vet Med Sci. 1996, 56: 355–357.
  • van der Linden IF, Voermans JJ, van der Linde-Bril EM, Bianchi AT, Steverink PJ. Virological kinetics and immunological responses to a porcine reproductive and respiratory syndrome virus infection of pigs at different ages. Vaccine. 2003, 21:1952-7.
  • Vanhee M, Van Breedam W, Costers S, Geldhof M, Noppe Y, Nauwynck H. Characterization of antigenic regions in the porcine reproductive and respiratory syndrome virus by the use of peptide-specific serum antibodies. Vaccine. 2011, 29:4794-804.
  • Vanhee M, Costers S, Van Breedam W, Geldhof MF, Van Doorsselaere J, Nauwynck HJ. A variable region in GP4 of European-type porcine reproductive and respiratory syndrome virus induces neutralizing antibodies against homologous but not heterologous virus strains. Viral Immunol. 2010, 23:403-13.
  • Van Reeth K, Labarque G, Nauwynck H, Pensaert M. Differential production of proinflammatory cytokines in the pig lung during different respiratory virus infections: correlations with pathogenicity. Res Vet Sci. 1999, 67:47-52.
  • Vézina SA, Loemba H, Fournier M, Dea S, Archambault D. Antibody production and blastogenic response in pigs experimentally infected with porcine reproductive and respiratory syndrome virus. Can J Vet Res. 1996, 60:94-9.
  • Walsh KP, Mills KH. Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol. 2013, 34:521-30.
  • Wang G, Song T, Yu Y, Liu Y, Shi W, Wang S, Rong F, Dong J, Liu H, Cai X, Zhou EM. Immune responses in piglets infected with highly pathogenic porcine reproductive and respiratory syndrome virus. Vet Immunol Immunopathol. 2011, 142:170-8.
  • Wang R, Nan Y, Yu Y, Yang Z, Zhang YJ. Variable interference with interferon signal transduction by different strains of porcine reproductive and respiratory syndrome virus. Vet Microbiol. 2013, 166:493-503.
  • Weesendorp E, Morgan S, Stockhofe-Zurwieden N, Popma-De Graaf DJ, Graham SP, Rebel JM. Comparative analysis of immune responses following experimental infection of pigs with European porcine reproductive and respiratory syndrome virus strains of differing virulence. Vet Microbiol. 2013, 163:1-12.
  • Yang L, Frey ML, Yoon KJ, Zimmerman JJ, Platt KB. Categorization of North American porcine reproductive and respiratory syndrome viruses: epitopic profiles of the N, M, GP5 and GP3 proteins and susceptibility to neutralization. Arch Virol. 2000, 145: 1599–619.
  • Yoon IJ, Joo HS, Christianson WT, Kim HS, Collins JE, Morrison RB, Dial GD. An indirect fluorescent antibody test for the detection of antibody to swine infertility and respiratory syndrome virus in swine sera. J Vet Diagn Inv. 1992, 4:144–7.
  • Yoon IJ, Joo HS, Goyal SM, Molitor TW. A modified serum neutralization test for the detection of antibody to porcine reproductive and respiratory syndrome virus in swine sera. J Vet Diagn Invest. 1994, 6:289-92.
  • Yoon KJ, Zimmerman JJ, Swenson SL, McGinley MJ, Eernisse KA, Brevik A, Rhinehart LL, Frey ML, Hill HT, Platt KB. Characterization of the humoral immune response to porcine reproductive and respiratory syndrome (PRRS) virus infection. J Vet Diagn Invest. 1995, 7:305-12.
  • Yoon KJ, Wu LL, Zimmerman JJ, Hill HT, Platt KB. Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol. 1996, 9:51-63.
  • Yoon KJ, Wu LL, Zimmerman JJ, Platt KB. Field isolates of porcine reproductive and respiratory syndrome virus (PRRSV) vary in their susceptibility to antibody dependent enhancement (ADE) of infection. Vet Microbiol. 1997, 55:277-87.
  • Zimmerman JJ, Benfield DA, Dee SA, Murtaugh MP, Stadejek T, Stevenson GW, Torremorell M. Porcine reproductive and respiratory syndrome virus (porcine arterivirus). In: 10th ed. Diseases of swine, Ed. Wiley-Blackwell. 2012, 31:463-86.

Download "THE BOOK FOR PRRS KNOWLEDGE":

The book is a compendium of answers to the main questions posed by professionals, students and researchers when they are face to face with PRRS on a daily basis. DOWNLOAD it now for FREE!



    Basic Personal Data Protection information:

    Controller: LABORATORIOS HIPRA, S.A.
    Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
    Lawful basis: Performance of the contractual relationship and HIPRA's legitimate Interest.
    Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
    Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

    For further information, please check our detailed information on Data Protection.
    Powered by Convert Plus

      NEWSLETTER
      DON'T MISS ANY UPDATES
      Basic Personal Data Protection information:
      Controller: LABORATORIOS HIPRA, S.A.
      Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
      Lawful basis: Performance of the contractual relationship and HIPRA's legitimate Interest.Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
      Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

      For further information, please check our detailed information on Data Protection.

      [mc4wp_checkbox]
      I have read and agree to the Privacy Policy and Basic information on Data Protection.
      close-image

      Informazioni di base sulla protezione dei dati personali:

      Titolare del trattamento: LABORATORIOS HIPRA, S.A.
      Finalità: Gestione del rapporto contrattuale e/o commerciale con HIPRA, incluso l’invio di notizie, promozioni e inviti a eventi sponsorizzati da HIPRA.
      Base giuridica: Esecuzione del rapporto contrattuale e del legittimo interesse di HIPRA.
      Destinatari: Terzi a cui HIPRA ha affidato servizi di cloud computing, sicurezza, auditing, mailing, supporto tecnico e informatico, nonché società del suo gruppo.
      Diritti: Richiedere l'accesso e la rettifica o la cancellazione dei dati personali e altri diritti come spiegato nelle informazioni aggiuntive. Puoi vedere le informazioni aggiuntive dettagliate sulla protezione dei dati nella nostra Informativa sulla privacy.

      Per ulteriori informazioni, puoi consultare le nostre informazioni dettagliate sulla Protezione dei dati.

      Basic Personal Data Protection information:

      Controller: LABORATORIOS HIPRA, S.A.
      Purposes: Managing the contractual and/or business relationship with HIPRA, including sending news, promotions and invitations to events sponsored by HIPRA.
      Lawful basis: Performance of the contractual relationship and HIPRA's legitimate Interest.
      Recipients: Third parties to which HIPRA has entrusted cloud computing, security, auditing, mailing, technical and computer support services, as well as companies in its group.
      Rights: Request access to and rectification or erasure of personal data and other rights as explained in the additional information. You can seeview the detailed additional information about data protection in our Privacy Policy.

      For further information, please check our detailed information on Data Protection.

      Información básica sobre protección de datos:

      Responsable del tratamiento: LABORATORIOS HIPRA, S.A.
      Propósitos: Gestionar la relación contractual y comercial con HIPRA, incluido el envío de noticias, promociones e invitaciones a eventos patrocinados por HIPRA.
      Fundamentos legales: Cumplimiento de la relación contractual e interés legítimo de HIPRA.
      Destinatarios: Terceros a los que HIPRA ha encargado las tareas de computación en la nube, seguridad, auditoría, correo, servicios de soporte técnico e informático, así como empresas de su grupo.
      Derechos: Solicitar el acceso y la rectificación o eliminación de los datos personales y otros derechos, tal como se explica en la información adicional. Puede ver la información adicional detallada sobre la protección de datos en nuestra Política de Privacidad.

      Para obtener más información, consulte nuestra información detallada sobre Protección de datos.